Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis

Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis

Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled part...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ERJ open research 2017-07, Vol.3 (3)
Hauptverfasser: Byrne, Anthony L., Marais, Ben J., Mitnick, Carole D., Garden, Frances L., Lecca, Leonid, Contreras, Carmen, Yauri, Yaninna, Garcia, Fanny, Marks, Guy B.
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page
container_title ERJ open research
container_volume 3
creator Byrne, Anthony L.
Marais, Ben J.
Mitnick, Carole D.
Garden, Frances L.
Lecca, Leonid
Contreras, Carmen
Yauri, Yaninna
Garcia, Fanny
Marks, Guy B.
description Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10–70 years with a history of drug-susceptible (DS)- or multidrug-resistant (MDR)-TB who had completed treatment and were clinically cured. Unexposed participants without TB were randomly selected from the same districts. We assessed respiratory symptoms, relevant environmental exposures, and spirometric lung function pre- and post-bronchodilator. In total, 144 participants with DS-TB, 33 with MDR-TB and 161 unexposed participants were fully evaluated. Compared with unexposed participants, MDR-TB patients had lower lung volumes (adjusted mean difference in forced vital capacity −370 mL, 95% CI −644– −97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27–18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio
doi_str_mv 10.1183/23120541.00026-2017
format Article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5507160</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_5507160</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_55071603</originalsourceid><addsrcrecordid>eNqlzLFqwzAUhWERKElo8gRZ9AJOdWVb9pQltPQBOnURsiIlCrIV7pVS-vZ1oEvnTge-Az9jOxB7gL5-kTVI0TawF0JIVUkB3YKtH1o9eMW2RNf5g1b2jVJLtpJ9B51q6jX7PF4wTcFyE9DH9MXTQBmLzSFN3PjskFOx1hH5EnlGZ_LopsyT52OJOZywnCt0FCibmXMZHNoS0wwb9uRNJLf93Wd2eHv9OL5XtzKM7mTnDJqobxhGg986maD_PlO46HO667YVHShR_zvwAwdBYuQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Byrne, Anthony L. ; Marais, Ben J. ; Mitnick, Carole D. ; Garden, Frances L. ; Lecca, Leonid ; Contreras, Carmen ; Yauri, Yaninna ; Garcia, Fanny ; Marks, Guy B.</creator><creatorcontrib>Byrne, Anthony L. ; Marais, Ben J. ; Mitnick, Carole D. ; Garden, Frances L. ; Lecca, Leonid ; Contreras, Carmen ; Yauri, Yaninna ; Garcia, Fanny ; Marks, Guy B.</creatorcontrib><description>Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10–70 years with a history of drug-susceptible (DS)- or multidrug-resistant (MDR)-TB who had completed treatment and were clinically cured. Unexposed participants without TB were randomly selected from the same districts. We assessed respiratory symptoms, relevant environmental exposures, and spirometric lung function pre- and post-bronchodilator. In total, 144 participants with DS-TB, 33 with MDR-TB and 161 unexposed participants were fully evaluated. Compared with unexposed participants, MDR-TB patients had lower lung volumes (adjusted mean difference in forced vital capacity −370 mL, 95% CI −644– −97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27–18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio &lt;0.70 (adjusted OR 2.47, 95% CI 1.01–6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management of chronic respiratory disease should be explored. Treated MDR-TB results in loss of lung volume; MDR-TB and susceptible TB can result in chronic airflow obstruction http://ow.ly/yM9H30bRDha</description><identifier>EISSN: 2312-0541</identifier><identifier>DOI: 10.1183/23120541.00026-2017</identifier><identifier>PMID: 28717643</identifier><identifier>PMID: 28344981</identifier><language>eng</language><publisher>European Respiratory Society</publisher><subject>Original</subject><ispartof>ERJ open research, 2017-07, Vol.3 (3)</ispartof><rights>Copyright ©ERS 2017 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507160/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507160/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Byrne, Anthony L.</creatorcontrib><creatorcontrib>Marais, Ben J.</creatorcontrib><creatorcontrib>Mitnick, Carole D.</creatorcontrib><creatorcontrib>Garden, Frances L.</creatorcontrib><creatorcontrib>Lecca, Leonid</creatorcontrib><creatorcontrib>Contreras, Carmen</creatorcontrib><creatorcontrib>Yauri, Yaninna</creatorcontrib><creatorcontrib>Garcia, Fanny</creatorcontrib><creatorcontrib>Marks, Guy B.</creatorcontrib><title>Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</title><title>ERJ open research</title><description>Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10–70 years with a history of drug-susceptible (DS)- or multidrug-resistant (MDR)-TB who had completed treatment and were clinically cured. Unexposed participants without TB were randomly selected from the same districts. We assessed respiratory symptoms, relevant environmental exposures, and spirometric lung function pre- and post-bronchodilator. In total, 144 participants with DS-TB, 33 with MDR-TB and 161 unexposed participants were fully evaluated. Compared with unexposed participants, MDR-TB patients had lower lung volumes (adjusted mean difference in forced vital capacity −370 mL, 95% CI −644– −97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27–18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio &lt;0.70 (adjusted OR 2.47, 95% CI 1.01–6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management of chronic respiratory disease should be explored. Treated MDR-TB results in loss of lung volume; MDR-TB and susceptible TB can result in chronic airflow obstruction http://ow.ly/yM9H30bRDha</description><subject>Original</subject><issn>2312-0541</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqlzLFqwzAUhWERKElo8gRZ9AJOdWVb9pQltPQBOnURsiIlCrIV7pVS-vZ1oEvnTge-Az9jOxB7gL5-kTVI0TawF0JIVUkB3YKtH1o9eMW2RNf5g1b2jVJLtpJ9B51q6jX7PF4wTcFyE9DH9MXTQBmLzSFN3PjskFOx1hH5EnlGZ_LopsyT52OJOZywnCt0FCibmXMZHNoS0wwb9uRNJLf93Wd2eHv9OL5XtzKM7mTnDJqobxhGg986maD_PlO46HO667YVHShR_zvwAwdBYuQ</recordid><startdate>20170712</startdate><enddate>20170712</enddate><creator>Byrne, Anthony L.</creator><creator>Marais, Ben J.</creator><creator>Mitnick, Carole D.</creator><creator>Garden, Frances L.</creator><creator>Lecca, Leonid</creator><creator>Contreras, Carmen</creator><creator>Yauri, Yaninna</creator><creator>Garcia, Fanny</creator><creator>Marks, Guy B.</creator><general>European Respiratory Society</general><scope>5PM</scope></search><sort><creationdate>20170712</creationdate><title>Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</title><author>Byrne, Anthony L. ; Marais, Ben J. ; Mitnick, Carole D. ; Garden, Frances L. ; Lecca, Leonid ; Contreras, Carmen ; Yauri, Yaninna ; Garcia, Fanny ; Marks, Guy B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_55071603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Byrne, Anthony L.</creatorcontrib><creatorcontrib>Marais, Ben J.</creatorcontrib><creatorcontrib>Mitnick, Carole D.</creatorcontrib><creatorcontrib>Garden, Frances L.</creatorcontrib><creatorcontrib>Lecca, Leonid</creatorcontrib><creatorcontrib>Contreras, Carmen</creatorcontrib><creatorcontrib>Yauri, Yaninna</creatorcontrib><creatorcontrib>Garcia, Fanny</creatorcontrib><creatorcontrib>Marks, Guy B.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>ERJ open research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Byrne, Anthony L.</au><au>Marais, Ben J.</au><au>Mitnick, Carole D.</au><au>Garden, Frances L.</au><au>Lecca, Leonid</au><au>Contreras, Carmen</au><au>Yauri, Yaninna</au><au>Garcia, Fanny</au><au>Marks, Guy B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</atitle><jtitle>ERJ open research</jtitle><date>2017-07-12</date><risdate>2017</risdate><volume>3</volume><issue>3</issue><eissn>2312-0541</eissn><abstract>Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10–70 years with a history of drug-susceptible (DS)- or multidrug-resistant (MDR)-TB who had completed treatment and were clinically cured. Unexposed participants without TB were randomly selected from the same districts. We assessed respiratory symptoms, relevant environmental exposures, and spirometric lung function pre- and post-bronchodilator. In total, 144 participants with DS-TB, 33 with MDR-TB and 161 unexposed participants were fully evaluated. Compared with unexposed participants, MDR-TB patients had lower lung volumes (adjusted mean difference in forced vital capacity −370 mL, 95% CI −644– −97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27–18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio &lt;0.70 (adjusted OR 2.47, 95% CI 1.01–6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management of chronic respiratory disease should be explored. Treated MDR-TB results in loss of lung volume; MDR-TB and susceptible TB can result in chronic airflow obstruction http://ow.ly/yM9H30bRDha</abstract><pub>European Respiratory Society</pub><pmid>28717643</pmid><pmid>28344981</pmid><doi>10.1183/23120541.00026-2017</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2312-0541
ispartof ERJ open research, 2017-07, Vol.3 (3)
issn 2312-0541
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5507160
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A08%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20airflow%20obstruction%20after%20successful%20treatment%20of%20multidrug-resistant%20tuberculosis&rft.jtitle=ERJ%20open%20research&rft.au=Byrne,%20Anthony%20L.&rft.date=2017-07-12&rft.volume=3&rft.issue=3&rft.eissn=2312-0541&rft_id=info:doi/10.1183/23120541.00026-2017&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_5507160%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28717643&rfr_iscdi=true